|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date04 Nov 1996 |
Treatment patterns and clinical outcomes of Recombinant Follicle Stimulating Hormone in South Korean patients who received Controlled Ovarian Hyper-stimulation: Results from a retrospective observational chart review study
An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
100 Clinical Results associated with Ferring Pharmaceuticals Korea Co., Ltd.
0 Patents (Medical) associated with Ferring Pharmaceuticals Korea Co., Ltd.
100 Deals associated with Ferring Pharmaceuticals Korea Co., Ltd.
100 Translational Medicine associated with Ferring Pharmaceuticals Korea Co., Ltd.